Search research articles
Contact Us
Filters
Showing results (121-130 of 515) with videos related to
Page
of 52
Sort By:
Blood Cancer Journal
|
May 25, 2026
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey
Shaji Kumar, David Murray, Dirk R Larson, et al.
American Journal of Hematology
|
March 18, 2021
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review
Ghulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, et al.
The Oncologist
|
April 1, 2023
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
Rafael Fonseca, Thierry Facon, Mahmoud Hashim, et al.
Clinical Nephrology
|
December 19, 2017
High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy
Nicola Lepori, Wisit Cheungpasitporn, Sanjeev Sethi, et al.
Leukemia & Lymphoma
|
March 15, 2022
Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Katja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
The New England Journal of Medicine
|
January 18, 2018
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Robert A Kyle, Dirk R Larson, Terry M Therneau, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 8, 2003
An oncolytic measles virus engineered to enter cells through the CD20 antigen
Amanda D Bucheit, Shaji Kumar, Deanna M Grote, et al.
Blood
|
July 19, 2011
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
Rishi K Wadhera, Robert A Kyle, Dirk R Larson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 13, 2026
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement
Christopher R D'Angelo, Benjamin A Derman, Srinivas Devarakonda, et al.
Blood Cancer Journal
|
February 10, 2021
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
Li Pang, S Vincent Rajkumar, Prashant Kapoor, et al.
Page
of 52
Search research articles
Search
Showing results (121-130 of 515) with videos related to
Sort By:
Page
of 52
Blood Cancer Journal
|
May 25, 2026
Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey
Shaji Kumar, David Murray, Dirk R Larson, et al.
American Journal of Hematology
|
March 18, 2021
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review
Ghulam Rehman Mohyuddin, Kelly Koehn, Al-Ola Abdallah, et al.
The Oncologist
|
April 1, 2023
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma
Rafael Fonseca, Thierry Facon, Mahmoud Hashim, et al.
Clinical Nephrology
|
December 19, 2017
High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy
Nicola Lepori, Wisit Cheungpasitporn, Sanjeev Sethi, et al.
Leukemia & Lymphoma
|
March 15, 2022
Carfilzomib 56 mg/m<sup>2</sup> twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
Katja Weisel, Ajay K Nooka, Evangelos Terpos, et al.
The New England Journal of Medicine
|
January 18, 2018
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Robert A Kyle, Dirk R Larson, Terry M Therneau, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 8, 2003
An oncolytic measles virus engineered to enter cells through the CD20 antigen
Amanda D Bucheit, Shaji Kumar, Deanna M Grote, et al.
Blood
|
July 19, 2011
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
Rishi K Wadhera, Robert A Kyle, Dirk R Larson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 13, 2026
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement
Christopher R D'Angelo, Benjamin A Derman, Srinivas Devarakonda, et al.
Blood Cancer Journal
|
February 10, 2021
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
Li Pang, S Vincent Rajkumar, Prashant Kapoor, et al.
Page
of 52